SCHEMBL30349062

SCHEMBL30349062

CCN(C(=O)OC(C)(C)C)c1cnc(Cl)cc1-c1ccc(F)cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 6/20 0.41
LTB4R2 Q9NPC1 1/20 0.36
AAK1 Q2M2I8 5/20 0.34
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
EIF4E P06730 1/20 0.32
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRA4 P48169 1/20 0.32
GABRA6 Q16445 1/20 0.32
P2RX3 P56373 1/20 0.32
CCNT1 O60563 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29920669 0.84 GAA (0.37) GPBAR1AAK1P2RX3GAA
SCHEMBL30825489 0.82 KAT6A (0.40) GPBAR1
SCHEMBL30825425 0.81 GPBAR1 (0.39) GPBAR1AAK1HDAC1HDAC8HDAC6
SCHEMBL29920199 0.81 GPBAR1 (0.39) GPBAR1AAK1HDAC1HDAC8HDAC6
SCHEMBL30825419 0.80 GPBAR1 (0.38) GPBAR1AAK1P2RX3
SCHEMBL29919993 0.80 GPBAR1 (0.38) GPBAR1AAK1P2RX3
SCHEMBL30373155 0.79 GAA (0.35) GPBAR1AAK1P2RX3SMN1; SMN2GAA
SCHEMBL28364286 0.77 LTB4R2 (0.36) LTB4R2HDAC1HDAC8HDAC6SMN1; SMN2
SCHEMBL3629295 0.74 P2RX3 (0.32) AAK1P2RX3GAAMCOLN3
SCHEMBL29920335 0.74 P2RX3 (0.32) AAK1P2RX3GAAMCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263399-A1 CBL-B MODULATORS AND USES THEREOF SCHRÖDINGER, INC. 2025-08-21 US disclosed
US-12325697-B2 CBL-B modulators and uses thereof NIMBUS CLIO, INC. (US) 2025-06-10 US disclosed
CN-117858707-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 CN disclosed
US-20230086064-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086064-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC GPBAR1 2155/4885LTB4R2 1299/4885AAK1 887/4885
US-20250263399-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC GPBAR1 2155/4885LTB4R2 1299/4885AAK1 887/4885
US-12325697-B2 CBL-B modulators and uses thereof CBLB, CBL, CBLC GPBAR1 2155/4885LTB4R2 1299/4885AAK1 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.